First Time Loading...

Globeimmune Inc
OTC:GBIM

Watchlist Manager
Globeimmune Inc Logo
Globeimmune Inc
OTC:GBIM
Watchlist
Price: 0.0002 USD Market Closed
Updated: Mar 28, 2024

Intrinsic Value

GBIM latest financial reports are more than 6 years old.
GBIM doesn't have a meaningful market cap.

GlobeImmune, Inc. is a biopharmaceutical company. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of GBIM.

Key Points:
GBIM Intrinsic Value
Base Case
Not Available
Base Case Scenario

Fundamental Analysis

Financials

Balance Sheet Decomposition
Globeimmune Inc

Current Assets 9.4m
Cash & Short-Term Investments 8.7m
Other Current Assets 756k
Non-Current Assets 321.3k
PP&E 190.6k
Other Non-Current Assets 130.6k
Current Liabilities 4.1m
Accounts Payable 407.7k
Accrued Liabilities 286.7k
Other Current Liabilities 3.5m
Non-Current Liabilities 3.5m
Other Non-Current Liabilities 3.5m
Efficiency

Earnings Waterfall
Globeimmune Inc

Revenue
6.2m USD
Cost of Revenue
-127.2k USD
Gross Profit
6.1m USD
Operating Expenses
-8.2m USD
Operating Income
-2.1m USD
Other Expenses
0 USD
Net Income
-2.1m USD

Free Cash Flow Analysis
Globeimmune Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

GBIM Profitability Score
Profitability Due Diligence

Globeimmune Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

37/100
Profitability
Score

Globeimmune Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

GBIM Solvency Score
Solvency Due Diligence

Globeimmune Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
50/100
Solvency
Score

Globeimmune Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GBIM Price Targets Summary
Globeimmune Inc

There are no price targets for GBIM.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GBIM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GBIM Price
Globeimmune Inc

1M 1M
+0%
6M 6M
+0%
1Y 1Y
-75%
3Y 3Y
-100%
5Y 5Y
-100%
10Y 10Y
-100%
Annual Price Range
0.0002
52w Low
0.0002
52w High
0.0008
Price Metrics
Average Annual Return 175.51%
Standard Deviation of Annual Returns 320.83%
Max Drawdown -100%
Shares Statistics
Market Capitalization 10.1k USD
Shares Outstanding 50 325 000
Percentage of Shares Shorted 3.49%

GBIM Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Globeimmune Inc Logo
Globeimmune Inc

Country

United States of America

Industry

Biotechnology

Market Cap

10.1k USD

Dividend Yield

0%

Description

GlobeImmune, Inc. is a biopharmaceutical company. The company is headquartered in Louisville, Colorado. The company went IPO on 2014-07-02. The firm is engaged in development of products for the treatment of cancer and infectious diseases. The firm provides Tarmogen platform, which activate the immune system by stimulating a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines which predominately stimulate antibody production. Tarmogens also reduce the number and function of regulatory T cells, thus further enabling the antigen-specific cellular immune response. The firm's oncology product candidates include GI-6301, GI-6207 and GI-4000. The firm's infectious disease product candidates include GS-4774, GI-19000, GI-2010 and GI-18000.

Contact

COLORADO
Louisville
1450 Infinite Dr
+13036252700.0
https://www.globeimmune.com/

IPO

2014-07-02

Employees

-

Officers

President, Vice President of Finance, Treasurer & Secretary
Mr. C. Jeffrey Dekker CPA
Scientific Founder & Member of Scientific Advisory Board
Dr. Richard C. Duke
Scientific Founder & Chairman of The Scientific Advisory Board
Dr. Donald Bellgrau

See Also

Discover More